Home/Context Therapeutics/Martin Lehr

ML

Martin Lehr

Chief Executive Officer & Director

Context Therapeutics

Therapeutic Areas

Oncology Solid Tumors

Context Therapeutics Pipeline

Drug	Indication	Phase
CTIM-76	Solid tumors expressing Claudin 6 (CLDN6)	Phase 1
CT-95	Advanced solid tumors expressing Mesothelin (MSLN)	Phase 1
CT-202	Solid tumors expressing Nectin-4	Phase 1

Leadership Team at Context Therapeutics

Jennifer Minai-Azary, CPA

Chief Financial Officer

Karen Chagin, MD

Chief Medical Officer

Alex Levit, Esq

Chief Legal Officer

Christopher Beck, MBA

SVP of Operations

Jennifer Dashnau, PhD, MBA

SVP Technical Operations

Bruce Hug, MD, PhD

VP Clinical Development

Megan Schaeffer

VP, Clinical Operations

Lisa Cooper, PhD

Sr. Director of Regulatory Affairs

Senior Director of Program Management

Senior Director of Quality

View full Context Therapeutics profile